在阿尔茨海默病中,APOE4重编程微质脂质代谢:机制和治疗影响
Jiajie Chen1, Shuoyan Zhao1, Yingying Zhou1
1Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Bioscience trends
|August 20, 2025
概括
APOE ε4等位基因通过破坏微质脂质代谢,损害它们的功能和增加神经炎症来恶化阿尔茨海默病. 针对这些途径为阿尔茨海默病提供了新的治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 代谢过程中的代谢.
背景情况:
- 无脂蛋白E ε4 (APOE ε4) 基因是晚发性阿尔茨海默病 (AD) 的主要遗传风险因素.
- APOE ε4显著影响大脑脂质代谢,显著影响微质,导致能量缺陷和神经退行.
研究的目的:
- 综合审查微质APOE4驱动的脂质代谢失调如何加剧AD病理.
- 阐明APOE4诱导的神经炎症和受损微质功能背后的机制.
- 总结针对AD的微质中APOE4的治疗策略.
主要方法:
- 文献综述综合了目前关于AD的APOE4,微质功能和脂质代谢的研究.
- 分析分子通路,包括LilrB3,I型干扰素信号传递,PU.1/NF-κB,ER压力和SREBP2.
- 检查微质细胞化,神经炎症和神经元-微质相互作用.
主要成果:
- 微质APOE4破坏脂质新陈代谢,导致脂质滴积累,胆固醇过载和 lysosomal 功能受损.
- APOE4通过特定的信号通路激活神经炎症,并损害了粉样蛋白β,蛋白和突触的微质细胞能力.
- 由微质APOE4驱动的不调节的脂质代谢和神经炎症放大了神经毒性,破坏了神经元-微质通信.
结论:
- 微质脂质代谢失调是APOE4在AD病变发生中的核心作用.
- 针对微质中与APOE4相关的途径,特别是脂质代谢,为AD提供了有前途的治疗机会.
- 了解这些机制可以指导开发干预措施,以保护AD中的大脑功能.
相关概念视频
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260


